Pathogenesis and new insights into acute and chronic venous thrombosis

Le résumé fourni par la source

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), may affect up to 900,000 patients per year, resulting in approximately 300,000 deaths per year in the United States. 1 Rather than decreasing with our improved efforts at diagnosis and treatment, this incidence has remained constant over the past 30 years and appears to be even increasing. Treatment costs run in billions of dollars per year and are increasing with the widespread adoption of the more expensive direct oral anticoagulants (DOACs). 2 This does not even account for costs associated with the long-term problems resulting from VTE, including post-thrombotic syndrome (PTS) for DVT and chronic thromboembolic pulmonary hypertension (CTEPH) for PE.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.